PIP5K1C — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1518720	1.00	13/20
SCHEMBL1519003	0.89	12/20
SCHEMBL1518834	0.80	11/20
SCHEMBL1518865	0.72	11/20
SCHEMBL1518883	0.68	9/20
SCHEMBL1518633	0.66	8/20
SCHEMBL1518737	0.66	8/20
SCHEMBL1518970	0.66	8/20
SCHEMBL1518820	0.58	8/20
SCHEMBL1519020	0.71	7/20
SCHEMBL1518930	0.66	7/20
SCHEMBL1518837	0.52	7/20
SCHEMBL1518716	0.51	7/20
SCHEMBL1518648	0.60	6/20
SCHEMBL1518962	0.60	6/20
SCHEMBL799211	0.56	6/20
SCHEMBL1518817	0.55	6/20
SCHEMBL1518991	0.55	6/20
SCHEMBL1621321	0.53	6/20
SCHEMBL1518993	0.51	6/20

Clinical trials — most relevant to PIP5K1C by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway	PHASE4	COMPLETED
Myo-inositol for the Management of Poor Ovarian Responders: A Prospective Randomized Controlled Trial	PHASE2/PHASE3	UNKNOWN
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid	PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome	PHASE1/PHASE2	COMPLETED
STAR Cape+BKM120 MBC With Brain Met	PHASE2	COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	PHASE1/PHASE2	RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery	PHASE1	COMPLETED
Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung Cancer	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Partial PTEN Deletion in Breast Cancer	nan	UNKNOWN
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
The Study Aims to Investigate the Effects of Oral Inositols on Insulin-resistance in Children With Obesity.	nan	UNKNOWN
Study of the Pathophysiological Mechanisms Involved in Bleeding Events	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes	nan	COMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome	nan	COMPLETED
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
Investigating the Genetic Basis of Pseudoexfoliation Syndrome, Angle-closure Glaucoma and Primary Open-angle Glaucoma	nan	RECRUITING
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors	nan	UNKNOWN
PIK3CA in HER2+ BC and pCR Trial	nan	UNKNOWN
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PIP5K1C binder may also engage these)

Protein	Name	Similarity
O70161	—	1.000	O70161 →
Q5I6B8	—	1.000	Q5I6B8 →
D3ZSI8	—	1.000	D3ZSI8 →
Q5CZZ9	—	1.000	Q5CZZ9 →
P70181	—	0.996	P70181 →
PIP5K1B	Phosphatidylinositol 4-phosphate 5-kinase type-1 beta	0.994	landscape →
P70182	—	0.994	P70182 →
PIP5K1A	Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha	0.993	landscape →
SNRK	SNF-related serine/threonine-protein kinase	0.992	landscape →
G2WWH6	—	0.991	G2WWH6 →
Q5SVQ0	—	0.991	Q5SVQ0 →
Q96P47	—	0.991	Q96P47 →
Q9SRW9	—	0.991	Q9SRW9 →
MAP4K4	Mitogen-activated protein kinase kinase kinase kinase 4	0.990	landscape →
A2WYE9	—	0.990	A2WYE9 →
BRPF3	Bromodomain and PHD finger-containing protein 3	0.990	landscape →
Q382V9	—	0.990	Q382V9 →
Q0JGK4	—	0.990	Q0JGK4 →
Q8BJM7	—	0.990	Q8BJM7 →
Q9ARI6	—	0.990	Q9ARI6 →
S7WII9	—	0.990	S7WII9 →
Q75E62	—	0.990	Q75E62 →
Q84UP7	—	0.989	Q84UP7 →
G5EGA3	—	0.989	G5EGA3 →
Q64332	—	0.989	Q64332 →
Q80WL2	—	0.989	Q80WL2 →
Q8LPU5	—	0.989	Q8LPU5 →
Q9AWM8	—	0.989	Q9AWM8 →
Q7EZW6	—	0.989	Q7EZW6 →
G5EFI8	—	0.989	G5EFI8 →